Cancer cell replication machinery

The cancer cell replication machinery, primarily centered around the replisome, is a sophisticated multi-protein assembly responsible for the accurate and timely duplication of the genome during the S-phase of the cell cycle (Nature Reviews Molecular Cell Biology, 2016). In oncogenesis, this machinery is often hijacked or dysregulated to facilitate the rapid, unchecked proliferation characteristic of malignant cells (Cell, 2018). Key enzymatic components include DNA polymerases (alpha, delta, epsilon), helicases such as the MCM complex, and topoisomerases, which manage DNA supercoiling (PubMed, 2020). Therapeutic intervention targeting this machinery is a pillar of oncology, encompassing antimetabolites that deplete nucleotide pools and topoisomerase inhibitors that induce lethal DNA strand breaks (NCI, 2023). Modern approaches also target the DNA damage response (DDR) associated with replication stress, utilizing PARP inhibitors to achieve synthetic lethality in cancers with specific genetic vulnerabilities like BRCA mutations (StatPearls, 2024). While highly effective, these therapies often face challenges such as systemic toxicity due to effects on rapidly dividing healthy cells and the emergence of drug resistance (Nature Reviews Cancer, 2021).

Other names

ReplisomeDNA replication machineryCell cycle machineryDNA replication complex

Inhibition of DNA synthesis, induction of DNA damage, inhibition of DNA unwinding, and inhibition of DNA repair pathways.